基石药业-B（02616.HK）今日盘中大跌8.7%，引发市场关注。该公司今早宣布了一项折价配股计划，这可能是导致股价下跌的主要原因。
根据公告，基石药业计划配售8000万股新股，配售价为每股2.933港元，较4月1日收市价3.45港元折让约14.99%。这次配股将占公司扩大后已发行股本的约5.86%。公司预计通过此次配股净筹资约2.32亿港元。
公司表示，配售所得款项的90%将用于其"管线2.0"资产的进一步研发，特别是CS5001（一款处于临床阶段的ROR1 ADC）和CS2009（一款靶向PD-1、VEGFA及CTLA-4的三特异性分子）。剩余资金将用于其他一般公司用途。这显示公司正积极推进其研发管线，但也反映出其对额外资金的需求。
此次大幅折价配股可能引发市场对公司股权稀释的担忧，同时也反映了生物科技公司在当前市场环境下融资的挑战。投资者需要权衡公司未来发展潜力与短期股价压力，密切关注公司后续研发进展及资金使用情况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.